

- **Name :** Ilhwan Kim
  - **Current Position & Affiliation:** Associate Professor  
Department of Internal Medicine, Division of Medical  
Oncology, Inje University College of Medicine  
Haeundae Paik Hospital
  - **Country:** Korea
- 

• **Educational Background:**

1999.3 ~ 2005.2 M.D. College of Medicine, Inje University

2008.3 ~ 2014.8 Master of Science : Internal medicine, Postgraduate School, Inje University

2016.3 ~ 2019.8 Doctor's degree : Medical oncology, Postgraduate School, Inje University

• **Professional Experience:**

2013.5 ~ 2014.2 Fellowship, Hematology / Oncology, Haeundae Paik Hospital  
University of Inje College of Medicine, Busan, Korea

2014.3 ~ 2014.12 Fellowship, Oncology, Asan Medical Center  
University of Ulsan College of Medicine, Seoul, Korea

2015.1 ~ 2016.2 Clinical assistant Professor, Department of Oncology, Haeundae Paik Hospital  
University of Inje College of Medicine, Busan, Korea

2016.3 ~ 2020.3 Assistant Professor, Department of Oncology, Haeundae Paik Hospital  
University of Inje College of Medicine, Busan, Korea

• **Professional Organizations:**

Korean Medical Association  
Korean Association of Internal Medicine  
Korean Cancer Association  
Korean Association for Clinical Oncology  
Korean Cancer Study Group  
ASCO (American society of clinical oncology)

• **Main Scientific Publications:**

**Efficacy and safety of deferasirox estimated by serum ferritin and labile plasma iron levels in patients with aplastic anemia, myelodysplastic syndrome, or acute myeloid leukemia with transfusional iron overload.**

Transfusion. 2015 Mar 11. doi: 10.1111/trf.13036

**Expression of carbonic anhydrase 9 is a novel prognostic marker in resectable hepatocellular carcinoma.**

Virchows Arch. 2015 Apr;466(4):403-13. doi: 10.1007/s00428-014-1709-0

**Pulmonary Artery Sarcoma – Multimodality Imaging**

Journal of Clinical Imaging Science. Vol. 6. Issue 4. Oct-Dec 2016

**A PI3K p110-selective inhibitor enhances the efficacy of anti-HER2/neu antibody therapy against breast cancer in mice**

Onco-Immunology Article: e1421890 Published online: 16 Jan 2018

)  
**Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group.**

Ther Adv Med Oncol. 2019 Aug 23;11:1758835919871126. doi: 10.1177/1758835919871126

**Clinical characteristics of clear cell ovarian cancer : a retrospective multicenter experience of 308 patients in south korea**

Cancer Research and Treatment Vol52. 277~283 (<https://doi.org/10.4143/crt.2019.292>)